🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
149.40
-7.10 (-4.54%)
At close: Nov 18, 2026, 4:00 PM EST
150.00
+0.60 (0.40%)
After-hours: Nov 18, 2026, 4:48 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

AMVUTTRA’s next growth phase centers on expanding physician adoption and preserving access amid 2027 payer and 340B changes. TRITON-CM enrollment is 2,250, with results and potential market entry targeted around 2030.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

For joining. My name is Faisal Khurshid. I am one of the Senior Biotech Analysts here at Jefferies. We are here in London at the Jefferies Global Healthcare Conference. Really pleased to have with us this morning the management team of Alnylam Pharmaceuticals. We have Yvonne Greenstreet, CEO, Jeff Poulton, CFO, and Pushkal Garg, the CMO of the company. We got a lot to get through. Yvonne, can I pass it off to you for some opening remarks?

Yvonne Greenstreet
CEO, Alnylam Pharmaceuticals

Yeah. No, thank you, Faisal. Delighted to be here. We are very excited to be able to share with you our progress at Alnylam. If I think about what we are focused on in the company right now, it is making sure that we can drive continued commercial performance, and it is making sure that we can continue to drive the very exciting pipeline that we have at Alnylam. With that, I will hand it back to you.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Okay. Let's get right into the launch of AMVUTTRA in ATTR-CM. I guess let's focus on the U.S. launch so far. You guys have given some metrics around prescribers. You say this represents about a third of the total TTR prescribing base. What does it take to expand that, and can you talk about the progress so far?

Yvonne Greenstreet
CEO, Alnylam Pharmaceuticals

Yeah, no, that is a great question. Thank you, Faisal. I think it is worth taking a step back and just reflecting on what we have achieved with the launch to date, and I think just 18 months into the launch, we are actually very pleased with the substantial growth that we have seen. But we have also been clear that we have not been satisfied with the pace of demand, and this is particularly because of the enormous opportunity that there is in this market, TTR cardiomyopathy. It is a large market. It is a growing market. Most patients have not yet been treated. And actually, only a third of physicians that we have been targeting have prescribed AMVUTTRA.

There's a lot ahead for us, and we were keen, given that these one-third of physicians who've used AMVUTTRA prefer AMVUTTRA, we believe that it was important to be able to engage with the two-thirds of physicians that haven't yet prescribed AMVUTTRA. We implemented an expansion to our field force, and I think we have every conviction in that strategy, and we're delighted with progress. We're now up to 2,000 prescribers, and now we're very focused on how we can translate the engagement that we're having with these additional prescribers and the existing prescribers to make sure that we can drive conversion to actually AMVUTTRA patient starts, and that's absolutely where we're focused. It really all starts with the profile of AMVUTTRA, which we believe provides a compelling proposition to physicians.

If you think about the fact that the mechanism really addresses the disease at its source, if you think about the extensive data set that we've delivered with HELIOS-B, and actually we've increased the evidence generation, recently presenting some data at AHA, which showed that if patients receive AMVUTTRA early in their disease, they have disproportionate outcomes. Clearly really important for patients to start AMVUTTRA as soon as possible. Then I think the quarterly subcutaneous route of administration is also an advantage because physicians have verified adherence. We think we've got a compelling proposition for physicians, and what we need to do now is make sure that we can engage physicians with greater intensity and frequency to explain this proposition with them.

Also for the two-thirds of prescribers who haven't yet used AMVUTTRA, really addressing any concerns they may have around how best to use AMVUTTRA in their practices, because most of these physicians are used to prescribing pills, not injectables, and so may have anxieties around buy and bill or where patients are going to be able to access AMVUTTRA. We can fix all of this because if a physician wants to use AMVUTTRA and buy and bill, we can support them in doing that. If they don't, then we can help them refer patients to alternative sites of care. One of the things that I think we've done incredibly well as a company is engage with a network of a large number of infusion clinics across the U.S. So 90% of patients can access AMVUTTRA within 10 mi of where they live.

What we're doing now is really, it's all about execution. It's making sure that we are able to engage with physicians with the right frequency, the right intensity, make sure that we have much more precise targeting of who we're focusing on with respect to engagement, and also tailoring the messages around AMVUTTRA so we can meet physicians exactly where they are, because we know in cardiology, behavioral change takes some time, but we believe that we have the data set to support this, and we have the right team in place in the U.S. to support physicians through this. Our experience has been that once physicians use AMVUTTRA, they prefer it, and so our job is to make sure that we have an increasing number of physicians that are able to try AMVUTTRA when we know that experience with AMVUTTRA begets preference.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Great. Thank you, Yvonne, for that overview. I guess simply put, would you say the greater priority is depth versus breadth, or is it equally both?

Yvonne Greenstreet
CEO, Alnylam Pharmaceuticals

I think it is both. I think we have expanded our field force by about 25%, which is a meaningful increase, and we feel that with that increase, we can actually achieve both.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. Can you talk about, in terms of achieving breadth, you mentioned that you were working on enabling the buy and bill practices for-

Yvonne Greenstreet
CEO, Alnylam Pharmaceuticals

If that is what they want to do.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Yeah.

Yvonne Greenstreet
CEO, Alnylam Pharmaceuticals

If not, we can help support patients receiving AMVUTTRA at these alternative sites of care, these infusion clinics.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. Can you just talk a little bit more about how that works in terms of enabling these practices either to have buy and bill within their practice or to be able to send the patient elsewhere? Both of those sound like they are not necessarily easy things to do.

Yvonne Greenstreet
CEO, Alnylam Pharmaceuticals

Well, we've achieved that very successfully in the third of prescribers that are already using AMVUTTRA. We have a reimbursement team, we have a field team that is actually able to work with physicians, to work with systems to make sure that this is easy for them and it's actually frictionless. That's been our experience to date with a third of physicians that are using AMVUTTRA, so we have no doubt that that's going to be the same for the two-thirds of physicians that we're now addressing.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Excellent. Then in terms of expanding that, you've talked about the prescriber number, you've talked about the number of centers that are enabled to administer AMVUTTRA as well. What metrics should the investment community be looking out for, and what pace of change on those metrics should we be looking for?

Yvonne Greenstreet
CEO, Alnylam Pharmaceuticals

Well, we obviously have a number of metrics that we track. I think the metric that we've committed to sharing on an ongoing basis around prescriber expansion, you will see that metric on an ongoing basis.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. Then, in the midst of this, you've announced the departure of your Chief Commercial Officer. Can you comment on that and if that is portending any change in the commercial strategy as well?

Yvonne Greenstreet
CEO, Alnylam Pharmaceuticals

I think we've actually built a very robust commercial foundation at Alnylam. I think one that has delivered very well, and we're very proud of what we've built. What we're doing now, obviously, is driving the next wave of growth for AMVUTTRA, and I think new commercial leadership will help us do that. Clearly, we have a strategy in place around increasing the size of the field force and engaging with more physicians. I think we have every conviction that that strategy is going to bear fruit, and really now the focus is on really excellent execution.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. Then can you comment on, as you're looking for new commercial leadership, what is the skill set or direction that you're looking for here?

Yvonne Greenstreet
CEO, Alnylam Pharmaceuticals

Yeah. As I said, it is to drive the next era of growth for AMVUTTRA, but also to help with what we hope are going to be multiple launches beyond AMVUTTRA. Obviously somebody that is able to lead a high-performance team, somebody that has got experience in competitive, dynamic markets. We have a search ongoing, and we feel that we will be able to identify a really strong individual in the not-too-distant future.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Okay, great. I want to talk a little bit about access of the product. You have spoken in your earnings calls, et cetera, about the breadth of access that you have enabled. However, at the same time, as we are looking at some of the payer policies being put in place for next year on Medicare Advantage plans, we have seen UnitedHealth and Aetna put AMVUTTRA on a non-preferred tier. Can you talk about what you are doing from a payer access side and what we should expect?

Jeff Poulton
CFO, Alnylam Pharmaceuticals

Yeah, I will take this one. I think even with the step edits that you mentioned with United and Aetna, our current access position in the U.S. for AMVUTTRA remains very strong. We have about 99% of lives in the U.S. are covered under insurance policies that the patients have, and about 75% of those patients today would have first-line access to AMVUTTRA. Let us just sort of unpack the sort of the details of that. It is a heavy Medicare population in the U.S., and so about 50% of current patients have original or fee-for-service Medicare. That is a very good sort of payer channel for us. There are no policies, there is no payer management, there are no prior authorizations required, so that is sort of immediate access to first line. The Medicare Advantage portion of the market is about 35% of the patients on AMVUTTRA today.

This is the part of the market that we knew at the time of launch was possible, that we would see cross-management between D and B, and the United change in policy was the first one. That is about 10% of lives, and Aetna is about 5% of lives. The remainder of the market is primarily commercial, and that is the part of the market where step edits have been in place right out of the gate in terms of the launch in cardiomyopathy. In terms of the policy itself, if you look at the United policy itself, it grandfathers in existing patients. Patients that would have polyneuropathy do not have to step through a stabilizer. In terms of the definition of progression, there is not a lot of specifics there. There is no detail on what has to be met to meet the definition of that.

There's no amount of time that the patient has to be on a stabilizer. Additionally, for a progressive fatal disease, what we find are if a physician believes the most appropriate product for the patient is AMVUTTRA, the physician, through the appeals process, has the ability to move that patient forward. We're, of course, in a position with the resources that we have in place, we're able to support that as well.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Great. Thank you, Jeff. I understand that your access position has historically been in a very good spot and currently is in a good spot with the metrics that you lay out. I think the concern among the investment community is that these metrics that you're saying, like the 75% first-line coverage, is lower than it was before. How should we think about the dynamics of this and what you can do to sort of protect ability to get unfettered frontline access?

Jeff Poulton
CFO, Alnylam Pharmaceuticals

Yeah, I think for 2027, for the major Medicare Advantage plans, the two that we talked about are the ones that we know about. We don't think that there will be additional beyond that for 2027. Of course, these are plans that have the ability to review policies annually. The thing that we need to do to continue to position AMVUTTRA for first-line access is to continue to differentiate the product in terms of the clinical profile of it. That's what will put us in the best position to continue to maintain first-line access for AMVUTTRA.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. With respect to Medicare Advantage, should we think about that as a risk that 35% segment of the market that is Medicare Advantage right now could expand and eat into the 50% that is currently part B?

Jeff Poulton
CFO, Alnylam Pharmaceuticals

Yeah, I mean, I think I mentioned for 2027, we think we are a good way through the policy establishment process and are not aware of any beyond the two that we have talked about. But annually, that is a process that these plans go through. So it is possible that changes could occur in the future.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. On a related topic, I wanted to talk about the rule change on 340B Drug reimbursement. This used to be at ASP + 6%, and now the rule for 2027 is ASP - 28%. Can you address two things? One, how does that impact the business on AMVUTTRA with respect to the provider side economics? On the other hand, are you able to comment on the extent to which the AMVUTTRA business is exposed to this?

Jeff Poulton
CFO, Alnylam Pharmaceuticals

Yeah. You laid it out correctly. Let's talk about the economics prior to the change first, just to make sure it's clear to everybody. 340B institutions in the U.S. purchase AMVUTTRA at a statutory discount of WAC - 23.1%. As you said, before the rule change went into effect, they are reimbursed by the government at ASP + 6%. There's a substantial spread that they make on that, on a therapy that's on a list price basis annually, about $475,000 a year. That's a program that was put in place to support those institutions in treating underinsured and non-insured patients. The change that's been proposed that will go into effect on January 1, which is what you said, is the reimbursement from the government to these institutions that purchase 340B changes from ASP +6% to ASP - 28%.

The economics substantially change, right, for these institutions. The questions are, what is Alnylam going to do to continue to make sure that patients have access to AMVUTTRA, either through this program, 340B, or through another purchasing channel? What we've been clear about is we do intend to contract with these sites to make sure that purchases of AMVUTTRA remain economically viable. Let's talk about what the choices are for these sites in terms of how they would purchase the product. They can stay in the 340B channel, and based on what I described, unless we do contracting, they would be underwater on that. We intend to provide contracting and discounts, so that remains an economically viable path. That's one option.

The second option to continue to have these patients treated within the institutions is move out of the 340B channel into what we call the direct WAC purchase channel. They would purchase at list and get reimbursed at ASP +6% . Those are obviously very different implications for AMVUTTRA for Alnylam in terms of impact on price. If they stay in the 340B channel, given the additional discounting that we're going to provide, that would put pressure on our net price. If they move out of the 340B channel and purchase at WAC, that would be positive from a pricing perspective because we're not providing either the statutory discount or the additional discount that we're going to have to provide if they stay in the 340B channel. The third option for these institutions to keep patients within the institution would be to move patients into the part D channel.

That's not a good channel for patients, given that we're covered under the medical benefit. There would be friction there in terms of the pathway and the timeline to get patients on drug, and likely would result in increased cost to the patient in terms of out-of-pocket costs. The other option that they've got is to not buy and bill anymore, not keep the patients within the institution, but move them to alternate sites of care. Yvonne talked about the pretty significant network of third-party infusion clinics that are in existence today that would be happy to take that business, right, from the institutions if they want to push those patients outside. That's also sort of that WAC channel. Those institutions, those clinics purchase at WAC, and so that would be positive to us from a pricing perspective.

So it's difficult to say what the overall impact's going to be. It will ultimately depend on what choices these institutions make in terms of how they decide to purchase the product going forward. We're interacting with them directly right now on our contracting strategy. We're getting some feedback through those conversations. We expect to finalize our contracting approach and have that in place effective the middle of December. We've talked about not guiding until our year-end results call in February. That'll allow us to get five, six weeks of experience with the new rule and have a much better understanding of the choices that these institutions are making in terms of impact on price.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. With respect to the first option that you mentioned of being able to contract on those 340B purchases, 340B channel where you get ASP + 6%. Basic question, for option one, is that contracting that impacts your ASP?

Jeff Poulton
CFO, Alnylam Pharmaceuticals

It does not.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Okay.

Jeff Poulton
CFO, Alnylam Pharmaceuticals

Does not impact ASP.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Okay. Basically, you can pursue both kind of option set one and two without-

Jeff Poulton
CFO, Alnylam Pharmaceuticals

Yes.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

impacting option two, ASP +6% .

Jeff Poulton
CFO, Alnylam Pharmaceuticals

Correct.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. Okay. With respect-

Yvonne Greenstreet
CEO, Alnylam Pharmaceuticals

In fact, it's probably worth mentioning that many institutions are using both channels now, both 340B and purchasing it.

Jeff Poulton
CFO, Alnylam Pharmaceuticals

Yeah. There's no friction for the institutions to move 340B to WAC. As Yvonne said, they do that today. That's ultimately going to be a purchasing choice that they'll make going forward.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. If institutions move from 340B to non-340B purchasing of AMVUTTRA, can you talk about the relative prescriber economics of those non-340B AMVUTTRA purchases compared to 340B purchases of a stabilizer?

Jeff Poulton
CFO, Alnylam Pharmaceuticals

Yeah. I mean, this is a- So this is the second issue. We talked about potential implications for AMVUTTRA price going forward. The second question is, how much do the existing economics drive share within those institutions, and how might that change when the economics are-- there's compression on the economics that these institutions make? I think it's a difficult question for us to answer precisely. I think if you talk to physicians, they're going to tell you that they make choices based on what they think is best for their patient. I think the evidence that we see, and there's a variety of things that we can look at. We can look across, there's about 200 340B institutions that purchase AMVUTTRA from us today. We have very different shares across those 340B entities.

Even if you look within a single hospital 340B network, where they've got multiple physicians within that institution that are prescribing AMVUTTRA, will have very different shares within a single institution, which tells you the institution itself is not driving decisions based on economics. Our belief is that's the primary driver of why AMVUTTRA is prescribed today, and that will continue to be the case on a go-forward basis.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. Thank you, Jeff. That is a super helpful explanation. I just want to ask one more question on this topic, and then Pushkal, I will come to you, of course. Jeff, in terms of quantifying the kind of exposure of AMVUTTRA to the 340B channel or the kind of dollar sizing of the impact-

Jeff Poulton
CFO, Alnylam Pharmaceuticals

Yeah.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

is something that investors have been highly interested in that has been a bit difficult to kind of size. Can you comment on that?

Jeff Poulton
CFO, Alnylam Pharmaceuticals

Yeah. I mean, we have talked about the fact that we are going to need a little bit of time as we get into 2027 to understand the choices that they are making, which would have implications for price. Then we will also likely see, are we seeing anything from a demand signaling perspective in the first five, six weeks of the year? So, that is why we have talked about guiding in the middle of February rather than at JP Morgan this year. We understand there is a huge amount of interest in this, and I think when we guide, we will be transparent about the key assumptions that underpin that, including what we are assuming about the 340B impact.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. Understood. So Pushkal, I want to talk about TRITON-CM, which is your phase III study in TTR-CM for your next generation TTR silencer, nucresiran. Specifically, I want to talk about the changes that have been made to the trial. You have upsized it twice. I believe you commented that you are trying to enrich for earlier stage patients. Can you talk about the motivation behind those changes and the expected benefit from making these changes?

Pushkal Garg
CMO, Alnylam Pharmaceuticals

Yeah, absolutely. I'm glad you asked. I think there's been probably a lot of noise around this study for a while, and I think it's important that we talk about it. I think we had a lot of learnings coming out of HELIOS-B, really, that suggested that, A, a high potency silencer can have a beneficial aspect, both as a monotherapy as well as in combination. Two, that the patients who benefit the most from this sort of approach, therapeutic approach, are those earlier in their disease process, before there's too much amyloid built up in the heart. And three, that this is a whole body disease, and that looking at all-cause mortality captures better the benefit of the drug a little bit more than the cardiovascular mortality. You see benefits on both, but disproportionate on all-cause mortality. All those things were taken into account when we designed TRITON-CM.

We focused on all those elements now with a molecule that instead of having 85% silencing, has about 95% silencing and is twice a year as opposed to four times a year. And we enriched for early patients as well. Now, I think when CARDIO-TTRansform came around, I think people saw those as discordant in some ways from HELIOS-B, and actually from our perspective, they're 100% concordant. They showed that a less potent silencer has less effect. It did have benefit across a variety of the endpoints that were measured, but in every instance when those were compared in a meta-analysis, it was less than the more potent silencer, which was AMVUTTRA.

Two, they saw a benefit, while not in the overall population, they saw actually a statistically significant benefit in the subpopulation of patients with early disease, as we'd kind of expected, and they would have actually seen statistically significant benefits if they'd had all-cause mortality as part of their endpoint. All of that really affirmed some of the design choices. Now, the one thing that has changed that we've seen over time is that the background event rates, as these patients are getting diagnosed earlier and getting treated more with SGLT2 inhibitors, et cetera, that the background event rate is going down. And so we've actually enlarged our study now two times by 500 patients each, so 1,000 overall, to now a total of 2,250, really just to be as conservative as possible about background event rates in the placebo arm.

Obviously, you can have the most potent drug in the world, but if the background event rates aren't high enough, you can't see a benefit on top of that. And so we've taken the most conservative approach we can around that. Fortunately, enrollment is going very, very well, and actually having a broader population of patients allows us to accrue more events. This is an event-driven study, so we're maintaining our guidance that we think we'll have results and be able to bring this to market around the 2030 timeframe. But that's the rationale. It's not about anything about the effect size of the drug. It's really about the event rates that's led to this change.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. So two quick follow-ups on this idea of enriching for the earlier stage patients. Some of the concern among investors is that you will have a heavily stabilizer-treated background population as well, and that these earlier stage patients might also do quite well on a stabilizer, and that also in an event-driven study, as you mentioned, the events would still come from the more severe segment of the population that you enroll. Just briefly, what is your comment on those two concerns that exist?

Pushkal Garg
CMO, Alnylam Pharmaceuticals

Yeah, no, absolutely understand the concerns. First of all, I think what we have seen, again, in HELIOS-B, and I think again in CARDIO-TTRansform, is that there is a benefit in those earlier patients, even in a stabilizer-treated population, right? If you look even in the subset of patients in the eplontersen study, those who were in that NAC stage one, there would have been, in about 600 or 700 patients, there would have been a statistically significant outcomes benefit just there, and that was a very heavily pre-treated with stabilizer population. We have seen the same thing in HELIOS-B. And we have shared some clinical trial simulation that shows that effect size is likely to get even larger with a more potent silencer like nucresiran. So we have a lot of confidence in terms of that effect size, both as a monotherapy and in terms of combination.

Second thing is about event rates that you talked about in these earlier populations. And again, I think we are seeing that, and even in a modest-sized population of patients in the eplontersen study, with a less potent silencer, in a fixed duration study of only 30 months, they would have seen a stat sig benefit. Here we have an event-driven study, so I think we feel very good about the ability to pick up enough events. These patients continue to have events, there is no question. And these are the population that have modifiable events that we can benefit with our drug.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Got it. Thank you, Pushkal. So I know we are at time here. Yvonne, I just wanted to pass it back to you for any closing remarks you may have.

Yvonne Greenstreet
CEO, Alnylam Pharmaceuticals

Faisal, I think you've done a splendid job taking us through the Q&A. I think we've covered the topics that are of interest there and top of mind to investors. So thank you very much, Faisal.

Faisal Khurshid
Senior Biotech Analyst, Jefferies

Great. Thank you for joining us. Thank you to the investors who joined.